跳至主要内容
临床试验/NCT00318968
NCT00318968已完成4 期

Development of an Algorithm for Identification of Responders to Short Term Treatment With Esomeprazole (Nexium) in Primary Care

AstraZeneca38 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2006年5月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
AstraZeneca
入组人数
1,000
试验地点
38
主要终点
The primary efficacy variable is the patient's key complaint. A patient whose key complaint has been absent for the last 24 hour of the treatment period (2 weeks +/- 2 days) is defined as a PPI responder.

研究概览

简要总结

The primary purpose of the study is to develop, and test, an algorithm for identification of responders to empirical esomeprazole treatment in general practices.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients attending general practice due to symptoms suggestive of acid related disease and, according to normal routine, the GP would prescribe an acid-inhibiting agent

排除标准

  • Alarm symptoms
  • Pregnancy
  • Contraindications to Nexium

结局指标

主要结局

The primary efficacy variable is the patient's key complaint. A patient whose key complaint has been absent for the last 24 hour of the treatment period (2 weeks +/- 2 days) is defined as a PPI responder.

次要结局

  • To evaluate the response rate (absence of the key complaint for the last 3 days of the treatment period (2 weeks +/- 2 days)).

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (38)

Loading locations...

相似试验

Nexium RESPONSE Trial | 临床试验